In our current study, we found that MS-275, a class I HDAC-selective inhibitor (HDAC1, HDAC2, and HDAC3), lowered blood pressure, reduced blood vessel thickness, and inhibited inflammation in an Ang II-induced hypertensive animal model. Here, HDAC3 is linked to hypertensive disorder.